Correlation of T-cell immune response with spontaneous resolution and subsequent relapse of Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 47, Issue 5, 2006, Pages 871-876

  Wilson, W M ^a   Dua, U ^b   Grigg, A P ^a   Gandhi, Maher K ^b,c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

EBV; Hodgkin's lymphoma; Immune response; Regulatory T cell; Spontaneous resolution

Indexed keywords

BLEOMYCIN; CYTOMEGALOVIRUS ANTIBODY; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE; LATENT MEMBRANE PROTEIN 1; LYMPHOCYTE SURFACE MARKER; TUMOR ANTIGEN; VINBLASTINE; VIRUS PROTEIN;

ADULT; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CELLULAR IMMUNITY; CERVICAL LYMPHADENOPATHY; CONTROLLED STUDY; DISEASE COURSE; EPSTEIN BARR VIRUS; HERPES VIRUS INFECTION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ADULT; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNITY, CELLULAR; MALE; RECURRENCE; REMISSION, SPONTANEOUS; T-LYMPHOCYTES, REGULATORY;

EID: 33744934539     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600649562     Document Type: Article

References (23)

1. Drobyski, W and Qazi, R. (1989) Spontaneous regression in non-Hodgkin's lymphoma: Clinical and pathogenetic considerations Am J Hematol, 31, pp. 138-141.
2. Al-Yamany, M and Lozano, A and Nag, S and Laperriere, N and Bernstein, M. (1999) Spontaneous remission of primary central nervous system lymphoma: Report of 3 cases and discussion of pathophysiology J Neurooncol, 42, pp. 151-159.
3. Bang, S and Cheong, J and Yang, W. (2005) An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications Yonsei Med J, 46, pp. 426-430.
4. Parekh, S and Koduri, P. (2003) Spontaneous regression of HIV-associated Hodgkin's disease Am J Hematol, 72, pp. 153-154.
5. Taqi, A and Abdurrahman, M and Yakubu, A and Fleming, A. (1981) Regression of Hodgkin's disease after measles Lancet, 1, pp. 1112.
6. Graca, L. (2005) New tools to identify regulatory T cells Eur J Immunol, 35, pp. 1678-1680.
7. Jonuleit, H and Schmitt, E and Stassen, M and Tuettenberg, A and Knop, J and Enk, A. (2001) Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood J Exp Med, 193, pp. 1285-1294.
8. Gulley, M and Glaser, S and Craig, F and Borowitz, M and Mann, R and Shema, S and et al (2002) Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma Am J Clin Pathol, 117, pp. 259-267.
9. Sherritt, M and Bharadwaj, M and Burrows, J and Morrison, L and Elliott, S and Davis, J and et al (2003) Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy Transplantation, 75, pp. 1556-1560.
10. Duraiswamy, J and Burrows, J and Bharadwaj, M and Burrows, S and Cooper, L and Pimtanothai, N and et al (2003) Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions J Virol, 77, pp. 7401-7410.
11. Rickinson, A and Moss, D. (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection Annu Rev Immunol, 15, pp. 405-431.
12. Gandhi, M and Khanna, R. (2004) Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments Lancet Infect Dis, 4, pp. 725-738.
13. Gandhi, M and Wills, M and Okecha, G and Day, E and Hicks, R and Marcus, R and et al (2003) Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation Blood, 102, pp. 3427-3438.
14. Duraiswamy, J and Sherritt, M and Thomson, S and Tellam, J and Cooper, L and Connolly, G and et al (2003) Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma Blood, 101, pp. 3150-3156.
15. Alvaro, T and Lejeune, M and Salvado, M and Bosch, R and Garcia, J and Jaen, J and et al (2005) Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells Clin Cancer Res, 11, pp. 1467-1473.
16. Gandhi, M and Tellam, J and Khanna, R. (2004) Epstein-Barr virus-associated Hodgkin's lymphoma Br J Haematol, 125, pp. 267-281.
17. Frisan, T and Sjoberg, J and Dolcetti, R and Boiocchi, M and De Re, V and Carbone, A and et al (1995) Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease Blood, 86, pp. 1493-1501.
18. Marshall, N and Christie, L and Munro, L and Culligan, D and Johnston, P and Barker, R and et al (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma Blood, 103, pp. 1755-1762.
19. Diepstra, A and Niens, M and Vellenga, E and van Imhoff, G and Nolte, I and Schaapveld, M and et al (2005) Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma Lancet, 365, pp. 2216-2224.
20. Gandhi, M and Lambley, E and Marlton, P and Seymour, J and Wolf, M and Prince, H and et al (2005) LAG-3 expressing lymphocytes suppress EBV latent membrane protein-specific T cell function in Hodgkins lymphoma patients Ann Oncol, 16, pp. 84A.
21. Bollard, C and Aguilar, L and Straathof, K and Gahn, B and Huls, M and Rousseau, A and et al (2004) Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus + Hodgkin's Disease J Exp Med, 200, pp. 1623-1633.
22. Goedert, J and Cote, T and Virgo, P and Scoppa, S and Kingma, D and Gail, M and et al (1998) Spectrum of AIDS-associated malignant disorders Lancet, 351, pp. 1833-1839.
23. Khanna, R and Moss, D and Gandhi, M. (2005) Technology insight: applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies Nat Clin Pract Oncol, 2, pp. 138-149.